Recombinant Human Inosine triphosphate pyrophosphatase(ITPA)

Code CSB-YP874838HU
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP874838HU-B
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP874838HU
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP874838HU
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >85% (SDS-PAGE)
Target Names ITPA
Uniprot No. Q9BY32
Alternative Names C20orf37; dJ794I6.3; HLC14-06-P; Inosine triphosphatase (nucleoside triphosphate pyrophosphatase); Inosine triphosphatase; inosine triphosphatase-A; Inosine triphosphate pyrophosphatase; Inosine triphosphate pyrophosphohydrolase; Itpa; ITPA_HUMAN; ITPase; My049; My049 protein; Non canonical purine NTP pyrophosphatase; Non standard purine NTP pyrophosphatase; NTPase; nucleoside triphosphate diphosphatase; Nucleoside triphosphate pyrophosphatase; OK/SW-cl.9; OTTHUMP00000030094; OTTHUMP00000160459; Putative oncogene protein hlc14-06-p
Species Homo sapiens (Human)
Expression Region 2-194
Protein Length Full Length of Mature Protein
Tag Info The following tags are available.
N-terminal His-tagged
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Pyrophosphatase that hydrolyzes the non-canonical purine nucleotides inosine triphosphate (ITP), deoxyinosine triphosphate (dITP) as well as 2'-deoxy-N-6-hydroxylaminopurine triposphate (dHAPTP) and xanthosine 5'-triphosphate (XTP) to their respective monophosphate derivatives. The enzyme does not distinguish between the deoxy- and ribose forms. Probably excludes non-canonical purines from RNA and DNA precursor pools, thus preventing their incorporation into RNA and DNA and avoiding chromosomal lesions.
Gene References into Functions
  1. Inosine triphosphate pyrophosphatase dephosphorylates ribavirin triphosphate, and reduced enzymatic activity potentiates mutagenesis in hepatitis C virus. PMID: 30045981
  2. This study suggests that the polymorphisms in the ITPA gene influence the severity of anaemia during the first month of a DAA/RBV-based treatment in HCV-related cirrhosis. PMID: 28165327
  3. baseline testing of this single ITPA SNP might help to identify the subset of patients with the greatest risk for experiencing RBV-induced anaemia, which may be particularly helpful in those with underlying cardiovascular disease. In such patients, RBV-sparing regimens should be preferred. PMID: 28198349
  4. The authors analysed ITPA-deficient human and mouse cells, and revealed that ITPA deficiency induces MLH1/PMS2- and p53-dependent growth arrest and DNA instability in mammalian cells. PMID: 27618981
  5. ITPA variant rs1127354C>A significantly predict RBV-induced anaemia during the first 3 months of treatment and it is recommended to be assessed before RBV administration PMID: 28543275
  6. The ITPA gene polymorphism rs1127354 heterozygous genotype (CA) may influence Hemoglobin levels and protect against hemolytic anemia during ribavirin containing regimens for hepatitis C PMID: 28480960
  7. Four gene signature (PTEN, PIK3C2A, ITPA and BCL3) is an independent prognostic factors of both overall survival and disease-free survival in clear-cell renal-cell carcinoma. PMID: 27779101
  8. Inosine triphosphatase polymorphism appeared to correlate with anemia in- cidence and RBV dose reduction during SOF/RBV therapy. PMID: 28109022
  9. Inosine triphosphatase (IPTA) rs1127354 variants but not rs7270101 were found in Chinese patients infected with chronic hepatitis C. IPTA rs1127354 variants and related ITPase were not only related with ribavirin-induced hemolytic anemia but also directly affected the virological response to pegylated interferon plus ribavirin combination therapy in Chinese chronic hepatitis C virus-infected patients. PMID: 28723780
  10. This study concluded that HIV-infection seems to be interfering with the nucleotide metabolism in leukocytes, including CD4 lymphocytes, by decreasing ITPase expression, independently of ITPA genotype. PMID: 27792682
  11. A high prevalence of the ITPA polymorphisms associated with ribavirin-induced hemolytic anemia was found in Mexican Native Amerindians. PMID: 28233743
  12. ITPA gene is associated with protection of anemia in patients with chronic hepatitis during antiviral therapy. PMID: 26110293
  13. We concluded that ITPase activity plays an important function and that ATP concentration changes due to therapy are related to the Hb decreasing mechanism in the early period of therapy with HCV treatment PMID: 27040635
  14. The aim of the study was to investigate frequencies of TPMT and ITPA polymorphisms in Lithuanian inflammatory bowel disease patients and analyze their association with azathioprine-related adverse events. PMID: 26674571
  15. ITPA polymorphism was associated with RBV-induced anemia and thrombocytopenia in Egyptian patients with hepatitis C virus genotype 4 infection. PMID: 26880169
  16. Hyperbilirubinemia develops at early time points after simeprevir administration in most cases and is dependent on the ITPA genotype. PMID: 26223482
  17. Genetic variants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by peg-interferon and ribavirin treatment. PMID: 26104535
  18. polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes [meta-analysis] PMID: 26438033
  19. The association of IL28B and APOH single nucleotide polymorphisms (SNPs) with sustained virological response and of ITPA SNPs with anemia related phenotypes. PMID: 26670100
  20. The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in Ribavirin dosing during hepatitis C virus therapy with direct acting antiviral agents PMID: 26279293
  21. ITPA SNPs in Brazilian patients receiving antiviral therapy for chronic hepatitis had a great propensity for developing ribavirin-induced anaemia. PMID: 26154744
  22. genotyping of ATIC rs2372536 and ITPA rs1127354 variants or measuring ITPA activity could be useful to predict methotrexate response in children with juvenile idiopathic arthritis. PMID: 25240429
  23. Recessive ITPA mutations were associated with early infantile encephalopathy. PMID: 26224535
  24. results showed that patients with aberrant ITPase genotype (mutant homozygous or heterozygous), more likely to be myelosuppressed and show liver toxicity after treatment with 6-Mercaptopurine PMID: 26242828
  25. The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy. PMID: 25287171
  26. Results indicate a strong, significant, and independent role of VDR in the early development of ribavirin-induced anemia and confirm the ITPA function in the prediction of anemia at week 4. PMID: 25713999
  27. ITPA polymorphisms are associated with an improved likelihood of achieving sustained virological response resulting from the reduced risk of relapse following IFN and ribavirin combination therapy for HCV infection PMID: 25340831
  28. ITPA genotype may serve as a genetic marker for the improvement of risk stratification and therapy individualization for patients with acute lymphoblastic leukemia. PMID: 25303517
  29. The significant association was found between the rs1127354 ITPA gene polymorphism and protection against ribavirin-induced hemolytic anemia in the Ukrainian patients with chronic hepatitis C infection. PMID: 26030972
  30. Results show that in patients with F3-F4 chronic hepatitis C receiving telaprevir based therapy, ITPA genotype does not impact on the management of early anemia. PMID: 24760000
  31. Partial splenic embolism, in conjunction with triple combination therapy, is a useful and safe method to treat genotype 1b chronic hepatitis C patients with hypersplenism-induced thrombocytopenia PMID: 25743001
  32. the risk of mercaptopurine intolerance was decreased in acute lymphoblastic leukemia patients with 138 allele and 561 allele polymorphism in the ITPA gene PMID: 25120852
  33. important role in hepatitis C virus infection[review] PMID: 24659876
  34. For ITPA, the frequency of P32T allele was 3%. We did not observe any homozygous variant for TPMT and ITPA alleles. PMID: 24774509
  35. Irrespective of the protective effect of ITPA mutations, premenopausal females less likely develop ribavirin induced anemia. PMID: 23850877
  36. All ITPA polymorphisms considered were shown to be significantly associated with anemia onset in chronic hepatitis C treated patients. PMID: 23933495
  37. ITPA protects against ribavirin-induced anemia, but is not associated with sustained virological response rate. PMID: 24449403
  38. ITPA variants are associated with reduced risk of hepatitis C relapse. PMID: 24519039
  39. Study supports recent studies which point towards an important role for ITPase in cellular surveillance of rogue hematologic malignancy. PMID: 23547827
  40. Non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, inosine triphosphatase genotype is not associated with sustained virologic response. PMID: 23960450
  41. role of conserved residues in substrate specificity PMID: 23770441
  42. association between ribavirin (RBV) serum levels and SLC28A2 rs11854484 genotype, as well as the replicated association of ITPA and SLC28A3 genetic polymorphisms with RBV-induced anemia and treatment response PMID: 23195617
  43. We propose that the dimer of P32T variant subunit with wild-type subunit is degraded in cells similarly to the P32T homodimer explaining the level of loss of ITPA activity in heterozygotes. PMID: 23528839
  44. ITPA polymorphisms influenced the degree of anaemia but not thrombocytopenia during therapy of chronic hepatitis C genotype 6 infection. PMID: 23730840
  45. Rs1127354 ITPA polymorphism plays a decisive role in protecting against treatment-induced anemia and the need for ribavirin dose reduction in Egyptian hepatitis C patients. PMID: 23538996
  46. ITPA SNPs influence ribavirin-induced anemia in chronic hepatitis C. PMID: 23139603
  47. IL-28B polymorphisms and ITPA variants influence outcome of treatment for chronic hepatitis C with Peg-Interferon and ribavirin. PMID: 23301546
  48. an association was found between ITPA SNP genotype and treatment-induced anemia during a 4-week course of ribavirin monotherapy in patients with chronic hepatitis C PMID: 22460221
  49. patients with the ITPA-CC genotype showed a smaller decrease in platelet counts during natural interferon-beta/ribavirin combination therapy. PMID: 22554247
  50. ITPase C94A has been recognized in about 15% of Japanese bur recent studies on its relationship with thiopurine toxicity has not been clarified. PMID: 23126166

Show More

Hide All

Involvement in disease Inosine triphosphate pyrophosphohydrolase deficiency (ITPAD); Epileptic encephalopathy, early infantile, 35 (EIEE35)
Subcellular Location Cytoplasm.
Protein Families HAM1 NTPase family
Tissue Specificity Ubiquitous. Highly expressed in heart, liver, sex glands, thyroid and adrenal gland.
Database Links

HGNC: 6176

OMIM: 147520

KEGG: hsa:3704

STRING: 9606.ENSP00000369456

UniGene: Hs.415299

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1